{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T03:58:12Z","timestamp":1788235092314,"version":"build-2803163510"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T00:00:00Z","timestamp":1712275200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate the clinical efficacy and safety of baloxavir marboxil tablets in the treatment of influenza A.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>According to a random sequence generated by computer software, 200 patients with confirmed influenza A were divided into a study group and a control group with 100 cases in each group. Group allocation was concealed using sealed envelopes. The study group was treated with oral administration of baloxavir marboxil tablets, 40\u2009mg once. The control group was given oral oseltamivir capsules, 75\u2009mg twice a day, for five consecutive days. The therapeutic effects, symptom disappearance time and adverse drug reactions of the two groups after 5\u2009days of treatment were compared.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There was no significant difference in the total effective rate between the two groups (99% vs. 98%, <jats:italic>p<\/jats:italic>\u2009&amp;gt;\u20090.05). There was no significant difference in fever subsidence time (1.54\u2009\u00b1\u20090.66 d vs. 1.67\u2009\u00b1\u20090.71 d, <jats:italic>p<\/jats:italic>\u2009&amp;gt;\u20090.05), cough improvement time (2.26\u2009\u00b1\u20090.91 d vs. 2.30\u2009\u00b1\u20090.90 d, <jats:italic>p<\/jats:italic>\u2009&amp;gt;\u20090.05) and sore throat improvement time (2.06\u2009\u00b1\u20090.86 d vs. 2.09\u2009\u00b1\u20090.83 d, <jats:italic>p<\/jats:italic>\u2009&amp;gt;\u20090.05) between the two groups. There was no significant difference in the incidence of adverse drug reactions between the two groups (8% vs. 13%, <jats:italic>p<\/jats:italic>\u2009&amp;gt;\u20090.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Baloxavir marboxil tablets can be effectively used in the treatment of patients with influenza A and have a similar efficacy and safety profile as oseltamivir capsules.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2024.1339368","type":"journal-article","created":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T04:33:20Z","timestamp":1712291600000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Study on the clinical efficacy and safety of baloxavir marboxil tablets in the treatment of influenza A"],"prefix":"10.3389","volume":"11","author":[{"given":"Chaochao","family":"Qiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinchun","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengxing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongye","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saiduo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianpeng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jichan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,4,5]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3760\/cma.j.issn.1674-2397.2019.01.001","article-title":"Protocol for diagnosis and treatment of influenza (2018 revised version)","volume":"12","year":"2019","journal-title":"Chin J Clin Infect Dis"},{"key":"ref2","volume-title":"Influenza (Avian and other zoonotic)[R\/OL]","year":"2018"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/S0140-6736(17)33293-2","article-title":"Global seasonal influenza-associated mortality collaborator network. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study","volume":"391","author":"Iuliano","year":"2018","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.3969\/j.issn.1673-7202.2016.09.039","article-title":"Clinical control study on 229 cases of epidemic cold with light syndrome treated with Chinese medicine and Western medicine","volume":"11","author":"Li","year":"2016","journal-title":"World Chin Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"j2841","DOI":"10.1136\/bmj.j2841","article-title":"WHO downgrades oseltamivir on drugs list after reviewing evidence","volume":"357","author":"Kmietowicz","year":"2017","journal-title":"BMJ"},{"key":"ref6","volume-title":"Executive summary: the selection and use of essential medicines 2019: report of the 22nd WHO Expert Committee on the selection and use of essential medicines [EB\/OL]","year":"2019"},{"key":"ref7","volume-title":"FDA approves new drug to treat influenza","year":""},{"key":"ref8","volume-title":"Shionogi announces approval of XOFLUZA\u00ae (Baloxavir Marboxil) in Japan for the treatment of influenza types A and B infections in children and post-exposure prophylaxis for influenza","year":""},{"key":"ref9","doi-asserted-by":"publisher","first-page":"533","DOI":"10.3870\/j.issn.1004-0781.2019.04.028","article-title":"Baloxavir marboxil, a new antiviral drug against influenza virus","volume":"38","author":"Chen","year":"2019","journal-title":"Herald Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.coviro.2019.01.006","article-title":"Baloxavir marboxil: the new influenza drug on the market","volume":"35","author":"O'Hanlon","year":"2019","journal-title":"Curr Opin Virol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.antiviral.2018.10.008","article-title":"In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit","volume":"160","author":"Noshi","year":"2018","journal-title":"Antivir Res"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1056\/NEJMoa1915341","article-title":"Baloxavir Marboxil for prophylaxis against influenza in household contacts","volume":"383","author":"Ikematsu","year":"2020","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s40265-018-0899-1","article-title":"Baloxavir: first global approval","volume":"78","author":"Heo","year":"2018","journal-title":"Drugs"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"411","DOI":"10.14142\/j.cnki.cn21-1313\/r.2019.05.015","article-title":"Baloxavir marboxil, Xofluza. Chinese","volume":"29","author":"Li","year":"2019","journal-title":"J Med Chem"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/irv.12821","article-title":"Comprehensive assessment of amino acid substitutions in the trimeric RNA polymerase complex of influenza a virus detected in clinical trials of baloxavir marboxil","volume":"15","author":"Hashimoto","year":"2021","journal-title":"Influenza Other Respir Viruses"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/S1473-3099(20)30004-9","article-title":"Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Ison","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.jiac.2020.04.014","article-title":"Safety and effectiveness of baloxavir marboxil for the treatment of influenza in Japanese clinical practice: a postmarketing surveillance of more than 3000 patients","volume":"26","author":"Nakazawa","year":"2020","journal-title":"J Infect Chemother"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1056\/NEJMoa1716197","article-title":"Baloxavir Marboxil investigators group. Baloxavir Marboxil for uncomplicated influenza in adults and adolescents","volume":"379","author":"Hayden","year":"2018","journal-title":"N Engl J Med"},{"key":"ref19","volume-title":"Phase III CAPSTONE-2 study showed that baloxavir marboxil reduced symptoms in people at high risk of complications from the flu [EB \/OL]","year":"2019"},{"key":"ref20","volume-title":"Positive phase III results for baloxavir marboxil in people at high risk of complications from influenza to be presented at IDWeek 2018 [EB\/OL]","year":"2019"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"S734","DOI":"10.1093\/ofid\/ofx180.001","article-title":"Cap-dependent endonuclease inhibitor S-033188 for the treatment of influenza: results from a phase 3, randomized, double-blind, placebo-and active-controlled study in otherwise healthy adolescents and adults with seasonal influenza","volume":"4","author":"Portsmouth","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1093\/infdis\/jiz245","article-title":"Baloxavir and treatment-emergent resistance: public health insights and next steps","volume":"221","author":"Gubareva","year":"2020","journal-title":"J Infect Dis"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1186\/s12879-021-06494-w","article-title":"Clinical and virological outcomes with baloxavir compared with oseltamivir in pediatric patients aged 6 to <\u200912 years with influenza: an open-label, randomized, active-controlled trial protocol","volume":"21","author":"Ishiguro","year":"2021","journal-title":"BMC Infect Dis"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"5291","DOI":"10.3390\/molecules25225291","article-title":"Identification of novel influenza polymerase PB2 inhibitors using a Cascade docking virtual screening approach","volume":"25","author":"Zhao","year":"2020","journal-title":"Molecules"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1093\/jac\/dkaa393","article-title":"Pharmacokinetic and pharmacodynamic analysis of baloxavir marboxil, a novel cap-dependent endonuclease inhibitor, in a murine model of influenza virus infection","volume":"76","author":"Ando","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"e1010481","DOI":"10.1371\/journal.ppat.1010481","article-title":"Preclinical and clinical developments for combination treatment of influenza","volume":"18","author":"Koszalka","year":"2022","journal-title":"PLoS Pathog"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.antiviral.2018.07.006","article-title":"The clinically approved MEK inhibitor Trametinib efficiently blocks influenza a virus propagation and cytokine expression","volume":"157","author":"Schr\u00e4der","year":"2018","journal-title":"Antivir Res"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.antiviral.2017.03.024","article-title":"The MEK-inhibitor CI-1040 displays a broad anti-influenza virus activity in vitro and provides a prolonged treatment window compared to standard of care in vivo","volume":"142","author":"Haasbach","year":"2017","journal-title":"Antivir Res"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1080\/22221751.2020.1829082","article-title":"Targeting the endolysosomal host-SARS-CoV-2 interface by clinically licensed functional inhibitors of acid sphingomyelinase (FIASMA) including the antidepressant fluoxetine","volume":"9","author":"Schloer","year":"2020","journal-title":"Emerg Microbes Infect."},{"key":"ref30","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1080\/22221751.2021.2020598","article-title":"Pharmacologically induced endolysosomal cholesterol imbalance through clinically licensed drugs itraconazole and fluoxetine impairs Ebola virus infection in vitro","volume":"11","author":"Kummer","year":"2022","journal-title":"Emerg Microbes Infect"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"628","DOI":"10.3390\/v12060628","article-title":"Broad-Spectrum host-based antivirals targeting the interferon and lipogenesis pathways as potential treatment options for the pandemic coronavirus disease 2019 (COVID-19)","volume":"12","author":"Yuan","year":"2020","journal-title":"Viruses"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1111\/bph.15418","article-title":"Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS-CoV-2 infection in vitro","volume":"178","author":"Schloer","year":"2021","journal-title":"Br J Pharmacol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1093\/cid\/cis636","article-title":"Treatment with neuraminidase inhibitors for critically ill patients with influenza a (H1N1)pdm09","volume":"55","author":"Louie","year":"2012","journal-title":"Clin Infect Dis"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1339368\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T04:36:41Z","timestamp":1712291801000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1339368\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,5]]},"references-count":33,"alternative-id":["10.3389\/fmed.2024.1339368"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1339368","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,5]]},"article-number":"1339368"}}